FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
WALTHAM, Mass., Feb. 14, 2018 -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and CEO of the Company, will present a corporate update at the 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22, 2018.
Information on the presentation is as follows:
| Event: | RBC Capital Markets Global Healthcare Conference | |||||
| Date: | Thursday, February 22, 2018 | |||||
| Time: | 8:30 a.m. EDT | |||||
| Location: | Lotte New York Palace Hotel, New York, NY | |||||
A live webcast of the presentation will be available by visiting the Investors section of Radius' website at http://ir.radiuspharm.com/events.cfm. A replay of the webcast will be archived on Radius' website for 30 days following the presentation.
About Radius Health
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com, and follow us on Twitter and LinkedIn.
Investor Relations Contact:
Elhan Webb, CFA
Email: [email protected]
Phone: 617-551-4011
